Promises of Nanotherapeutics in Obesity
- 1 June 2019
- journal article
- review article
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 30 (6) , 369-383
Abstract
No abstract availableKeywords
Funding Information
- NIH (T32DK097718)
- NIDDK
- Morris L. Lichtenstein Jr Medical Research Foundation
This publication has 112 references indexed in Scilit:
- Reward-based hypertension control by a synthetic brain–dopamine interfaceProceedings of the National Academy of Sciences, 2013
- Therapeutic DNA Vaccination Using In Vivo Electroporation Followed by Standard of Care Therapy in Patients With Genotype 1 Chronic Hepatitis CMolecular Therapy, 2013
- Pharmaceutically controlled designer circuit for the treatment of the metabolic syndromeProceedings of the National Academy of Sciences, 2012
- miR‐33 controls the expression of biliary transporters, and mediates statin‐ and diet‐induced hepatotoxicityEMBO Molecular Medicine, 2012
- Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglyceridesNature, 2011
- Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosisJournal of Clinical Investigation, 2011
- miR-33 links SREBP-2 induction to repression of sterol transportersProceedings of the National Academy of Sciences, 2010
- MiR-33 Contributes to the Regulation of Cholesterol HomeostasisScience, 2010
- Harmonizing the Metabolic SyndromeCirculation, 2009
- Nanoparticles evading the reticuloendothelial system: Role of the supported bilayerBiochimica et Biophysica Acta (BBA) - Biomembranes, 2009